Lirk Philipp, Haller Ingrid, Colvin Hans Peter, Lang Leopold, Tomaselli Bettina, Klimaschewski Lars, Gerner Peter
Department of Anesthesiology and Critical Care Medicine, Innsbruck Medical University, Anichstr. 35, 6020 Innsbruck, Austria.
Anesth Analg. 2008 May;106(5):1456-64, table of contents. doi: 10.1213/ane.0b013e318168514b.
Animal models show us that specific activation of the p38 mitogen-activated protein kinase (MAPK) may be a pivotal step in lidocaine neurotoxicity, but this has not been investigated in the case of two very widely used local anesthetics, bupivacaine and ropivacaine. We investigated the hypotheses that these drugs (A) are less neurotoxic than the prototype local anesthetic, lidocaine (B) are selectively toxic for subcategories of dorsal root ganglion neurons and (C) induce activation of either p38 MAPK or related enzymes, such as the c-jun terminal N-kinase (JNK) and extracellular signal-regulated kinase (ERK).
We incubated primary sensory neuron cultures with doses of lidocaine, bupivacaine, and ropivacaine equipotent at blocking sodium currents. Next, we sought to determine potential selectivity of bupivacaine and ropivacaine toxicity on neuron categories defined by immunohistochemical staining, or size. Subsequently, the involvement of p38 MAPK, JNK, and ERK was tested using enzyme-linked immunosorbent assays. Finally, the relevance of MAPK pathways in bupivacaine- and ropivacaine-induced neurotoxicity was determined by selectively inhibiting activity of p38 MAPK, JNK, and ERK.
We found that the neurotoxic potency of bupivacaine and ropivacaine is dose-dependent and similar in vitro, but is not selective for any of the investigated subgroups of neurons. Neurotoxicity of bupivacaine and ropivacaine was mediated, at least in part, by MAPKs. Specifically, we demonstrated the relevance of both p38 MAPK and JNK pathways for the neurotoxicity of bupivacaine and characterized the involvement of the p38 MAPK pathway in the neurotoxicity of ropivacaine.
Given equipotent doses, the neurotoxic potential of lidocaine does not appear to be significantly different from that of bupivacaine and ropivacaine in vitro. Moreover, bupivacaine and ropivacaine do not exert their neurotoxicity differently on specific subsets of dorsal root ganglion neurons. Their neurotoxic effects are brought about through the activation of specific MAPKs; the specific pharmacologic inhibition of these kinases attenuates toxicity in vitro.
动物模型向我们表明,p38丝裂原活化蛋白激酶(MAPK)的特异性激活可能是利多卡因神经毒性的关键步骤,但对于两种广泛使用的局部麻醉药布比卡因和罗哌卡因,尚未对此进行研究。我们研究了以下假设:这些药物(A)的神经毒性低于原型局部麻醉药利多卡因;(B)对背根神经节神经元亚类具有选择性毒性;(C)诱导p38 MAPK或相关酶(如c-jun末端N激酶(JNK)和细胞外信号调节激酶(ERK))的激活。
我们用在阻断钠电流方面等效剂量的利多卡因、布比卡因和罗哌卡因孵育原代感觉神经元培养物。接下来,我们试图确定布比卡因和罗哌卡因对通过免疫组织化学染色或大小定义的神经元类别毒性的潜在选择性。随后,使用酶联免疫吸附测定法检测p38 MAPK、JNK和ERK的参与情况。最后,通过选择性抑制p38 MAPK、JNK和ERK的活性来确定MAPK途径在布比卡因和罗哌卡因诱导的神经毒性中的相关性。
我们发现布比卡因和罗哌卡因的神经毒性效力呈剂量依赖性,且在体外相似,但对任何研究的神经元亚组均无选择性。布比卡因和罗哌卡因的神经毒性至少部分由MAPK介导。具体而言,我们证明了p38 MAPK和JNK途径与布比卡因的神经毒性相关,并确定了p38 MAPK途径在罗哌卡因神经毒性中的作用。
在等效剂量下,利多卡因的神经毒性潜力在体外似乎与布比卡因和罗哌卡因没有显著差异。此外,布比卡因和罗哌卡因对背根神经节神经元的特定亚组没有不同的神经毒性作用。它们的神经毒性作用是通过特定MAPK的激活实现的;这些激酶的特异性药理抑制在体外可减轻毒性。